Muscular Dystrophy Canada fund nine new projects through 2023 grant program

NMD4C Investigators involved in many of these exciting clinical and translational research projects

On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.

This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.

2023 Clinical Research Projects

Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)

Dr Reshma Amin, respirologist and NMD4C investigator.

Project Lead

Dr Reshma Amin (NMD4C investigator)

The Hospital for Sick Children

NMD4C investigators and collaborators as project co-investigators and collaborators

Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)

Project Lead

Dr Tyler Churchward-Venne

McGill University

NMD4C member as project co-investigator

Dr Mark Tarnopolsky

Dr Mark Tarnopolsky

Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)

Hernan-Gonorazky_3x2

Project Lead

Dr Hernan Gonorazky (NMD4C investigator)

The Hospital for Sick Children

NMD4C investigator as project collaborator

B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)

Project Lead

Dr Eric Voorn

University of Amsterdam

NMD4C investigators and members as project co-investigators and collaborators

Dr Luc Hébert

Dr Luc Hébert

Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)

Project Lead

Dr Jill Glennis Zwi​​cker

University of British Columbia

NMD4C investigators and members as project co-investigators and collaborators

Translational Research Grants

Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)

james-dowling

Project Lead

Dr James Dowling (NMD4C investigator)

The Hospital for Sick Children

How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)

Project Lead

Dr Simon Gira​rd

Université du Québec à Chicoutimi

NMD4C investigators as project co-investigators

Evaluating the impact of stop variants  on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)

Martine tetreault

Project Lead

Dr Martine Tetreault (NMD4C member)

University of Montreal

Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)

Project Lead

Dr Pascal Chartra​​nd

University of Montreal

Muscular Dystrophy Canada have announced the nine projects funded through their 2023 research grants competition.

Read next...

Text reading: Cataloguing NMD Basic Research Expertise in Canada, image of researcher pipetting on the right.

NMD4C to Develop a List of Canadian Neuromuscular Research Labs to Support Research Collaborations and Training

We are excited to launch an initiative from the NMD4C cell and animal-based NMD research tasks to develop a centralized list of Canadian neuromuscular research labs, and we need your help to collect this information!

MDC and NMD4C now recruiting: clinical trials and community of practice manager

MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager

Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community and help bring clinical trials to Canada!

2024 NMD4C early-career awards now accepting applications

Annual NMD4C Early-Career Awards Program Accepting Applications

We are excited to launch the second year of the NMD4C Early-Career Awards for 2024!

NMD4C pre-clinical science team seeking trainee input. Let us know if you'd like to be involved in an advisory committee.

NMD4C Pre-clinical Science Pillar Seeking Trainee Input

The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you! 

Dr Natasha Chang and Dr Rashmi Kothary receive MDC Dr David Green Awards in 2023.

NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards

We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada

News update reading: Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.